Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 2Leukemia 2Infections 2Wilms Tumor 1Sarcoma 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1Neuroblastoma 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Biphenotypic, Acute 1Kidney Neoplasms 1Intraocular Lymphoma 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1Bronchiolitis Obliterans Syndrome 1Blast Crisis 1

Interventions

liposomal amphotericin B 1Voriconazole 1Micafungin 1Amphotericin B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Aspergillosis × Voriconazole × Clear all
NCT01207128 2012-04-20

Trial of Combination Antifungal Therapy (Vori+Mica vs. Vori+Placebo) in Invasive Aspergillosis

University of Arkansas

Phase 2 Withdrawn

Aspergillosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡